Clinical trial NCT02968784: Focal ExAblate MR-Guided Focused Ultrasound Treatment for Management of Organ-Confined Intermediate Risk Prostate Cancer
Official title: Focal ExAblate™ MR-Guided Focused Ultrasound (MRgFUS) Treatment for Management of Organ-Confined Intermediate Risk Prostate Cancer (OC-IRPC): Evaluation of Safety and Effectiveness
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Prostate Cancer
Keywords: Prostate Cancer
MRgFUS
ExAblate
Focused Ultrasound
Lead sponsor: InSightec
Sponsor class: INDUSTRY
First posted: 2016-11-21
Enrollment: 53
Sex: MALE
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is intended to show that ExAblate™ MRgFUS is a safe procedure that can significantly postpone or eliminate the need of patients with organ confined intermediate risk prostate cancer to undergo a definitive treatment (i.e., Radical Prostatectomy or Radiation therapy) for their disease.

Detailed description: This study will evaluate the proportion of patients with organ-confined intermediate risk prostate cancer (OC-IRPC) undergoing focal ExAblate™ MRgFUS prostate treatment that will be free of clinically significant PCa which requires definitive treatment at 2 years after completion of their ExAblate™ treatment and to demonstrate the safety of focal ExAblate™ MRgFUS treatment.

Clinically significant PCa requiring definitive treatment is defined as pathology findings from whole-gland, imaging-guided, extended mapping biopsy of Gleason Score (GS) \> 7

The primary efficacy endpoint in this trial, measured at 24 months with whole-gland extended imaging-guided mapping biopsy, is Response scored dichotomously for each subject as follows:

* Response = 0 ("Failure"): Positive mapping biopsy defined as Gleason Score \> 7 (indicating definitive treatment) in any part of their prostate gland
* Response = 1 ("Success"): Negative mapping biopsy defined as Gleason Score \< 7.

Safety of ExAblate™ treatment will be determined by evaluation of the incidence and severity of device related complications from the first treatment day visit throughout entire follow-up duration.

All adverse events will be captured and recorded. However, the safety of the ExAblate™ treatment will be defined by the incidence and severity of treatment or device related adverse events, grades III - V (CTCAE version 4.03; 2010-06-14).

Secondary Effectiveness Outcomes:

1. % of patients with negative 5-month follow-up biopsy results in the treated part of the prostate
2. Treatment effect on patients' Quality of Life (QoL), the following validated self-reported urogenital functioning assessment instruments will be used before and following treatment at pre-specified intervals.

   1. Urinary symptoms - IPSS
   2. Urinary continence - ICIQ-UI-SF
   3. Sexual function - IIEF-15
3. PSA levels and post-treatment PSA kinetics will also be assessed

Eligibility criteria: Inclusion Criteria:

* PSA ≤ 20 ng/ml
* Histologically proven PCa on imaging-guided transrectal or transperineal extended mapping biopsy
* Patient with intermediate risk, early-stage organ-confined prostate cancer (T1a up to T2b, N0, M0) and voluntarily chooses ExAblate thermal ablation as the non-invasive treatment, who may currently be on wtachful waiting or active surveillance and not in need of imminent therapy
* Gleason Score 7 (3+4 or 4+3) based on mapping prostate biopsy with no more than 15mm cancer in maximal linear dimension in any single core
* Single hemilateral index Gleason 7 lesion identified in the prostate based on biopsy mapping with supporting MRI findings; may have secondary Gleason 6 lesion on ipisilateral or contralateral side confirmed with biopsy and/or MRI

Exclusion Criteria:

* Any Contraindication to MRI, such as: over-size limitations avoiding patient's positioning in the bore of MRI scanner, claustrophobia, implanted ferromagnetic materials or foreign objects, or known contraindication to utilization of MRI contrast agent (e.g., Gadolinium/Magnevist)
* History of prostatectomy, radiation therapy to the pelvis for any other malignancy, brachytherapy, Cryotherapy, US-guided HIFU, orchiectomy, prostate photodynamic therapy, or prostate cancer-specific chemotherapy
* Patient under androgen deprivation therapy (ADT), alpha reductase inhibitors, and/or other hormonal treatment within the past 6 months
* Any rectal disease, pathology, anomaly, injury, previous treatment, or scarring which could change acoustic properties of the rectal wall, or might prevent safe probe insertion (e.g., inflammatory bowel disease, fistula, stenosis, fibrosis, or symptomatic hemorrhoids
* History of an invasive malignancy other than basal or squamous skin cancers in the last 5 years
* Existing urethral or bladder neck contracture/stricture
* Prostatitis NIH categories I, II and III
* Implant near (\<1cm) the prostate

Primary outcomes:
measure: The primary efficacy endpoint in this trial measured with whole-gland extended imaging-guided mapping biopsy, is Response scored dichotomously; success vs. failure
timeFrame: 24 months post treatment
measure: Adverse events
timeFrame: 24 months post treatment
Secondary outcomes:
measure: Percent of patients with negative biopsy
timeFrame: 5 months post treatment
measure: Quality of Life - urinary symptoms - IPSS questionnaire score
timeFrame: 24 months post treatment
measure: Quality of Life - urinary continence - ICIQ-SF questionnaire score
timeFrame: 24 months post treatment
measure: Quality of Life - sexual function - IIEF-15 questionnaire score
timeFrame: 24 months
measure: Prostate Specific Antigen (PSA)
timeFrame: 24 months post treatment
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Toronto General Hospital
state: Ontario
city: Beijing
country: China
facility: Beijing Hospital
state: Beijing
city: Shanghai
country: China
facility: Changhai Hospital of Shanghai
state: Shanghai
city: London
country: United Kingdom
facility: St. Mary's Hospital
Study officials:
affiliation: Toronto General Hospital
name: Sangeet Ghai, MD
role: PRINCIPAL_INVESTIGATOR
References: